Abstract: An under sleeper pad (1) for fastening to an outer surface (2) facing a ballast bed (16), in particular an underside, of a railroad sleeper (3). The under sleeper pad (1) includes an elastomer layer (5), the elastomer layer (5) having a density in the range of 250 kg/m3 to 350 kg/m3, preferably 250 kg/m3 to 330 kg/m3.

Abstract: A method for determining neighborhood relationships between an actuator and sensors that interact with the an actuator in an installation for controlling a technical process and that communicate with the actuator, wherein the actuator influences the process and the sensors capture measured values of process variables, where the actuator influences the process in accordance with a predefined test pattern, searches for the predefined test pattern in sequences of measured values received from the sensors as responses to the test pattern, and identifies the sensor whose response best satisfies a predefined quality criterion in terms of response quality and response time as the sensor with the greatest operative proximity to the actuator.

Abstract: A field device and method for parameterizing a field device via a parameter, wherein to provide validation, a first checking characteristic is calculated by the field device based on the parameter and a device ID stored, where the first checking characteristic is transferred to an engineering system, the parameter to be validated and the device ID are additionally transferred to the engineering system and are output on a display, where to confirm correct parameterization, a user can input the read first checking characteristic at an operating unit of the engineering system, which first checking characteristic is then transferred back to the field device, where the received checking characteristic is compared with the calculated checking characteristic to validate the parameter such that external calculations of checking characteristics are advantageously unrequired and relation of the validation to the correct field device is ensured.

Abstract: In order to effectively protect a particle measuring device (8) against temperatures that are too high and/or too low, it is provided that the temperature (T) of the sample gas is measured upstream of a first temperature-sensitive sample gas processing or sample gas measuring device (20, 21, 22, 42) in the particle measuring device (8) and that the measured temperature (T) is compared with a first and/or second limit value (To, Tu) and that the particle measuring device (8) is switched into a safe mode if the measured temperature (T) exceeds the first limit value (To) or falls below the second limit value (Tu).

Abstract: Compounds of general Formula I: wherein R1, R2, R3, x, A and Ra are as defined herein are inhibitors of cyclin-dependent kinases and are useful for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.

Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.

Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.

Abstract: Compounds of general formula (I): are useful as inhibitors of cyclin dependent kinases such as CDK9.

Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.

Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.

Abstract: The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.

Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. formula (I).

Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.

Abstract: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).

Abstract: The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.

Abstract: are useful as inhibitors of cyclin dependent kinases such as CDK9.

Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.

Abstract: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).

Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. formula (I).

Abstract: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceutical compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.